1. CAMBRIDGE, Mass., Nov. 18, 2021 /PRNewswire/ -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing platform, today announced that Mahesh Karande, President and Chief Executive Officer, Roger Sawhney, M.D., Chief Financial Officer, and Thomas McCauley, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference taking place from November 29December 2, 2021. A recording of the fireside chat will made available on Monday, November 22nd at 10:00 a.m. ET.

    The recording of…

    View Full Article
  2. CAMBRIDGE, Mass., Nov. 10, 2021 /PRNewswire/ -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced financial results for the third quarter ended September 30, 2021.

    "We continue to progress our pioneering OMEGA platform and our pipeline of Omega Epigenomic Controllers (OECs) with our first candidate, OTX-2002 for the treatment of hepatocellular carcinoma, which we believe is one of many potential therapeutic applications of our platform, currently advancing through Investigational New Drug (IND)-enabling studies…

    View Full Article
  3. CAMBRIDGE, Mass., Nov. 9, 2021 /PRNewswire/ -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced that Mahesh Karande, President and Chief Executive Officer, and Thomas McCauley, Ph.D., Chief Scientific Officer, will present at the Jefferies London Healthcare Conference on Wednesday, November 17, 2021 at 8:00 a.m. GMT.

    A live webcast of the presentation will be available on the Investors & Media section of the Company's website at www.omegatherapeutics.com. An archived replay of the presentation will be available…

    View Full Article
  4. CAMBRIDGE, Mass., Oct. 14, 2021 /PRNewswire/ -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced a strategic research collaboration with researchers at the Stanford University School of Medicine to explore the therapeutic potential of Omega Epigenomic Controllers (OECs) to control ocular disease genes associated with inflammation or regeneration of ocular tissues.

    Under the terms of the collaboration, Omega and members of the Ophthalmology Department of Stanford University School of Medicine will use the OMEGA Epigenomic Programming…

    View Full Article
  5. CAMBRIDGE, Mass., Sept. 27, 2021 /PRNewswire/ -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced that Mahesh Karande, President and Chief Executive Officer, will participate in a fireside chat at the Chardan Virtual 5th Annual Genetic Medicines Conference on Monday, October 4, 2021 at 8:30 a.m. ET.

    A live webcast of the fireside chat will be available on the Investors & Media section of the Company's website at www.omegatherapeutics.com. An archived replay of the fireside chat will be available on the same website for approximately…

    View Full Article